Association Between BRCA Status and P53 Status in Breast Cancer: A Meta-Analysis

BACKGROUND: Research on BRCA mutation has meaningful clinical implications, such as identifying risk of second primary cancers and risk of hereditary cancers. This study seeks to summarize available data to investigate the association between BRCA status and P53 status by meta-analysis. MATERIAL/METHODS: We searched PubMed, Embase, and Cochrane library databases for relevant studies. Meta-analysis was conducted using STATA software. We summarized odds ratios by fixed-effects or random-effects models. RESULTS: This study included a total of 4288 cases from 16 articles, which including 681 BRCA1 mutation carriers (BRCA1(Mut)), 366 carriers of BRCA2 mutation (BRCA2(Mut)), and 3241 carriers of normal versions of these genes. BRCA1(Mut) was significantly associated with P53 over-expression compared with BRCA2(Mut) (OR 1.851, 95% CI=1.393–2.458) or non-carriers (OR=2.503, 95% CI=1.493–4.198). No difference was found between p53 protein expression in BRCA2 (Mut) carriers and non-carriers (OR=0.881, 95% CI=0.670–1.158). CONCLUSIONS: Our meta-analysis suggests that BRCA1(Mut) breast cancer patients are more likely to have P53 overexpression compared with BRCA2(Mut) and non-carriers. This information provides valuable information for clinicians who perform related studies in the future.